CASC-674

CASC-674 is a preclinical-stage monoclonal antibody that targets **T-cell immunoreceptor with Ig and ITIM domains (TIGIT)**, an inhibitory receptor expressed on T cells and Natural Killer (NK) cells. Developed through a collaboration between **Cascadian Therapeutics** and **Adimab LLC**, CASC-674 was designed to block the interaction between TIGIT and its ligands, thereby preventing the negative regulation of immune responses and enhancing the body's ability to attack tumor cells. Following the acquisition of Cascadian Therapeutics by **Seattle Genetics** (now **Seagen**, a subsidiary of **Pfizer**) in early 2018, the program's development under this specific designation appears to have ceased, likely as part of portfolio prioritization or integration into Seagen's broader immuno-oncology pipeline.